Immatics N.V.
Develops T-cell redirecting immunotherapies (ACT & TCR Bispecifics) for solid tumor cancers.
IMTX | NDAQ
Overview
Corporate Details
- ISIN(s):
- NL0015285941
- LEI:
- Country:
- United States of America
- Address:
- PAUL EHRLICH-STRASSE 15, 72076 TUBINGEN
- Website:
- https://immatics.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Immatics N.V. is a clinical-stage biopharmaceutical company focused on the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. The company leverages its proprietary platforms to identify cancer targets and engineer high-affinity T-cell receptors (TCRs). Its pipeline comprises two primary therapeutic modalities: Adoptive Cell Therapies (ACT) and TCR Bispecifics. Immatics is a global leader in the precision targeting of PRAME, a protein expressed in over 50 types of cancer, developing a broad franchise of therapies for patients with solid tumors and significant unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Immatics N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Immatics N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Immatics N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
